Exacerbation Reduction in Severe Eosinophilic Asthma Based on Eosinophil Thresholds

被引：0
|
作者：
Yancey, Steven W. [1 ]
Mayer, Bhabita
Gunsoy, Necdet
Keene, Oliver N.
Bleecker, Eugene G. [2 ]
Brightling, Christopher [3 ]
Pavord, Ian [4 ]
机构：
[1] GlaxoSmithKline, Resp Med Franchise, Res Triangle Pk, NC USA
[2] Wake Forest Sch Med, Ctr Genom & Personalized Med, Winston Salem, NC USA
[3] Univ Hosp Leicester NHS Trust, Inst Lung Hlth, Leicester, Leics, England
[4] Univ Oxford, Resp Med, Oxford, England
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2016年 / 137卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2015.12.1120
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
677
引用
收藏
页码：AB208 / AB208
页数：1
相关论文
共 50 条
  • [11] Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthma
    Youngwoo Choi
    Duy Le Pham
    Dong-Hyun Lee
    So-Hee Lee
    Seung-Hyun Kim
    Hae-Sim Park
    Experimental & Molecular Medicine, 2018, 50 : 1 - 8
  • [12] Asthma Exacerbation Profile on open label treatment with Benralizumab for severe eosinophilic asthma [BenRex]
    Logan, Jennifer
    Wetherall, Kirsty
    Gillespie, Lynsey
    Mcconnachie, Alex
    Lee, Wai-Ting Nicola
    Burhan, Hassan
    Brown, Thomas
    Faruqi, Shoaib
    Jackson, David J.
    Kurukulaaratchy, Ramesh
    Mansur, Adel H.
    Saralaya, Dinesh
    Fowler, Stephen J.
    Patel, Pujan
    Brown, James
    Lordan, James
    Siddiqui, Salman
    Smith, Steven J.
    Mistry, Vijay
    Brown, Vanessa
    Shah, Peer Ameen
    Djukanovich, Ratko
    Pavord, Ian D.
    Heaney, Liam G.
    Brightling, Christopher E.
    Chaudhuri, Rekha
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [13] Efficacy of mepolizumab in severe eosinophilic asthma by baseline eosinophil count and exacerbation history: Meta-analysis of two phase 3 trials
    Albers, F.
    Howarth, P.
    Bratton, D.
    Yancey, S.
    Bradford, E.
    Kwon, N.
    ALLERGY, 2019, 74 : 455 - 456
  • [14] Blood Eosinophil Phenotype During Treatment With Mepolizumab in Patients With Severe Eosinophilic Asthma
    Sakai, C.
    Matsuyama, M.
    Nakajima, M.
    Matsumura, S.
    Nonaka, M.
    Arai, N.
    Kuramoto, K.
    Yoshida, K.
    Morishima, Y.
    Muratani, M.
    Hizawa, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [15] Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
    Howarth, Peter
    Quirce, Santiago
    Papi, Alberto
    Israel, Elliot
    Mallett, Stephen
    Bates, Stewart
    Yancey, Steve
    Albers, Frank C.
    Kwon, Namhee
    ALLERGY, 2020, 75 (08) : 2085 - +
  • [16] Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma
    Ortega, Hector
    Katz, Lynn
    Hartley, Benjamin
    Yancey, Steve
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [17] Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma
    Ortega, Hector
    Katz, Lynn
    Gunsoy, Necdet
    Keene, Oliver
    Yancey, Steven
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 136 (03) : 825 - +
  • [18] Late Breaking Abstract - Role of eosinophil mitochondrial function in severe eosinophilic asthma
    Koranteng, Janice
    Raby, Katie
    Dixey, Piers
    Lai, Sook Ling
    Howarth, Peter
    Chung, Kian Fan
    Michaeloudes, Charalambos
    Bhavsar, Pankaj
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [19] Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
    Jackson, David J.
    Korn, Stephanie
    Mathur, Sameer K.
    Barker, Peter
    Meka, Venkata G.
    Martin, Ubaldo J.
    Zangrilli, James G.
    DRUG SAFETY, 2020, 43 (05) : 409 - 425
  • [20] Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
    David J. Jackson
    Stephanie Korn
    Sameer K. Mathur
    Peter Barker
    Venkata G. Meka
    Ubaldo J. Martin
    James G. Zangrilli
    Drug Safety, 2020, 43 : 409 - 425
12345